



## ASX/Media Release

### Benitec Moves Operations to Sydney, Replaces Chief Financial Officer

**5 August 2011, Melbourne, Australia:** Benitec Ltd (ASX:BLT), a world leader in gene silencing for human therapeutics, announced today that its Chief Financial Officer and Company Secretary Mr John Rawling will end his employment with the Company effective 24 August 2011. Mr Greg West will officially take over as Chief Financial Officer from that date.

Mr Rawling, who has been with Benitec for the past five years, was appointed Chief Financial Officer in April 2007 and has served the position with distinction. The reason for his decision relates to the relocation of Benitec's operations to Sydney, where the Chief Executive Officer, Dr Peter French, is based.

Dr French said, "The Company is grateful to John for his contribution to Benitec, in particular his hard work and attention to detail over the years, and we wish him well for the future."

Benitec's Sydney office is located at F6A/1-15 Barr Street, Balmain NSW 2041. Joining Dr French and Mr West in the office is Ms Ching Chung, Benitec's Administration Assistant.

Benitec's registered office remains at Level 16, 356 Collins Street, Melbourne, Vic, 3000.

#### For Further Information

Dr Peter French  
Chief Executive Officer  
Tel: +61 (0)412 457 595

[pfrench@benitec.com](mailto:pfrench@benitec.com)

#### About Benitec [www.benitec.com](http://www.benitec.com)

Benitec Limited is developing novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and, potentially, to cure disease results from its demonstrated ability to permanently silence genes which cause the condition.

Benitec now either owns or exclusively licences from CSIRO more than 40 granted or allowed patents in the field of RNA interference for human therapeutic applications. Patents have been granted in key territories such as the USA, the UK, Japan, Europe, Canada and Australia. In addition, Benitec has almost 50 patent applications pending for which it is the owner or exclusive licensee from CSIRO, and has further intellectual property under development as a result of its pipeline program.

Benitec trades on the Australian stock exchange under the symbol "BLT". The Company was founded in 1997 and has been publicly held since 2001. The Company aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. In-house it is pursuing a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, as well as programs with licensees that have advanced to pre-clinical and/or clinical trials.